• Indian Indices
  • Global Indices
  • Commodities
  • Currency
Sensex
  • Sensex
  • Nifty
{{x.close_price| number:2}} {{x.netchg| number:2}} ({{x.perchg | number:2}}%)
Open - {{x.open | number:2}}
Prev Close - {{x.prevclose|number:2}}
Today's High - {{x.high|number:2}}
Today's Low - {{x.low|number:2}}
Advances/Declines (30 Companies)
  • 1D
  • 1W
  • 1M
  • 1Yr
  • 5Yr
{{x.upd_time}}
FTSE 100
  • FTSE 100
  • DJIA
  • NIKKEI 225
  • HANG SENG
{{x.Date}}
{{x.close| number:2}} {{x.Chg | number:2}} ({{x.PChg | number:2}}%)
Open - {{x.close | number:2}}
Prev Close - {{x.PrevClose|number:2}}
Gold
  • Gold
  • Silver
  • Crude Oil
  • Copper
{{x.Trd_Date}} ( {{x.Time}} )
{{x.ClosePrice| number:2}} {{x.change| number:2}} ({{x.perchange | number:2}}%)
Exchange - MCX
Open - {{x.Open|number:2}}
Exp Date - {{x.Exp_Date}}
Today's High - {{x.High|number:2}}
Prev. Close - {{x.PrevClose|number:2}}
Today's Low - {{x.Low|number:2}}
USDINR
  • USDINR
  • GBPINR
  • EURINR
  • JPYINR
{{x.Lasttrdtime}} ( {{x.Time}} )
{{x.ltp| number:2}} {{x.PriceDiff| number:2}} ({{x.PerChange | number:2}}%)
Exchange - NSE
Open - {{x.Open|number:2}}
Exp Date - {{x.Expirydate}}
Today's High - {{x.High|number:2}}
Prev. Close - {{x.PrevPrice|number:2}}
Today's Low - {{x.Low|number:2}}
As On 11-Aug-2022 EOD, Market Closed
SENSEX
59,332.60
515.31 (0.88%)
NIFTY
17,659.00
124.25 (0.71%)
    No Companies Visited

Back to news list
  • Dr Reddy's Lab rises after acquiring Eton Pharma's injectable portfolio

    Dr. Reddy's Laboratories gained 1.41 to Rs 4,370.50 after the drug maker said it acquired a portfolio of branded and generic injectable products from US-based Eton Pharmaceuticals, Inc.

    The portfolio includes the Biorphen (phenylephrine hydrocholoride) injection and Rezipres (ephedrine hydrochloride) injection NDAs with nine separate combinations of strengths... The portfolio includes the Biorphen (phenylephrine hydrocholoride) injection and Rezipres (ephedrine hydrochloride) injection NDAs with nine separate combinations of strengths and presentations and one first-to-file approved ANDA for Cysteine Hydrochloride for the U.S. one strength each of Biorphen and Rezipres are currently commercially available in the U.S. The acquisition will complement Dr. Reddy's U.S. institutional business with limited competition injectable products. Under the terms of the agreement, Dr. Reddy's acquired the Eton portfolio for an upfront payment of approximately $5 million in cash, plus contingent payments of up to $45 million. The acquisition supports Dr. Reddy's efforts to accelerate and expand affordable medications for patients. Marc Kikuchi, chief executive officer, North America Generics, Dr. Reddy's, said, "Long before the COVID-19 pandemic, there have been concerns about access to some critical care products for hospitals and health systems. This acquisition provides our North America organization with a foundational footprint to help address products that are not always readily available for patients. For these and many other reasons, I believe we are well-positioned to integrate the portfolio and grow the business."

    According to IQVIA, the value of total addressable market for these products in the U.S. is approximately $174 million for the calendar year ending in April 2022.

    Meanwhile, Dr Reddy's Laboratories on Friday said it has entered into a settlement agreement with Indivior Inc. and Indivior UK, and Aquestive Therapeutics, Inc. Pursuant to the agreement, the company will receive payments totalling $72 million by 31 March 2024. The said agreement resolves all claims between the parties relating to the company's generic buprenorphine and naloxone sublingual film, 2 mg/0.5 mg, 4 mg/1 mg, 8 mg/2 mg, and 12 mg/3 mg dosages, including Indivior's and Aquestive's patent infringement allegations and the company's antitrust counterclaims. As part of the settlement, the underlying litigation will be dismissed.

    Dr Reddy's Laboratories is an integrated pharmaceutical company. It offers a portfolio of products and services including APIs, custom pharmaceutical services, generics, biosimilars and differentiated formulations. Its major markets include – USA, India, Russia & CIS countries, and Europe.

    The pharmaceutical major's consolidated net profit tumbled 82.6% to Rs 97 crore on a 15% increase in revenue from operations to Rs 5436.80 crore in Q4 FY22 over Q4 FY21.



    Back to news list
Previous Stories :
More






Hot Pursuit News

Quick Links

Market Statistics

Formed in 1986, Capital Market Publishers India Pvt Ltd pioneered corporate databases and stock market magazine in India. Today Capitaline corporate database cover more than 35,000 listed and unlisted Indian companies. Latest technologies and standards are constantly being adopted to keep the database user-friendly, comprehensive and up-to-date.

Over the years the scope of the databases has enlarged to cover economy, sectors, mutual funds, commodities and news. Many innovative online and offline applications of these databases have been developed to meet various common as well as customized requirements.

While all the leading institutional investors use Capitaline databases, Capital Market magazine gives access to the databases to individual investors through Corporate Scoreboard. Besides stock market and company-related articles, the magazine’s independent and insightful coverage includes mutual funds, taxation, commodities and personal finance.

The power of the database is harnessed by our fired-up reporters to generate interesting ideas. The reader-friendly presentation of the idea, supplemented by relevant data and information, can be accessed online through Capita Telefolio and Telefolio Gold. These ideas are used by individual investors as well as institutional investors to do further research and stay ahead.

Capital Market Publishers India Pvt. Ltd.

401, Swastik Chambers, Sion Trombay Road, Chembur, Mumbai - 400 071.
91-22-25229720
9769005430
Kindly note www.capitalmarket.com does not send any mobile SMS, whatsapp or twitter messages
giving any kind of stock recommendations.
For Capital Market Magazine queries mail to : subscription@capitalmarket.com
For Capital Market Online Products related queries mail to : financeshop@capitalmarket.com
For any other Capital Market Website related Queries mail to : info@capitalmarket.com
To advertise on Capital Market Websites & Capital Market Fortnightly magazine mail to : advt@capitalmarket.com
Flash News 11-Aug-2022
  •  ( 14:33) Nifty hovers above 17,650; Fin. services shares rises  
  •  ( 13:37) Sensex spurts 455 pts, European shares advance  
  •  ( 13:19) PB Fintech net loss widens to Rs 204 crore in Q1  
  •  ( 13:02) Radico Khaitan Q1 PAT decline 3% YoY to Rs 58 cr  
  •  ( 12:21) Abbott India Q1 PAT rises 5% YoY to Rs 205 cr  
  •  ( 11:57) Oil India Q1 PAT soars to Rs 1,555 cr  
  •  ( 11:34) Indices trade with strong gains; Nifty hovers at 17,650  
  •  ( 10:58) Patanjali Foods Q1 PAT jumps 39% YoY to Rs 241 cr  
  •  ( 10:34) Barometers turn range bound; Nifty hovers above 17,650  
  •  ( 10:08) Coal India Q1 PAT zooms 179% to Rs 8,833 cr  
  •  ( 10:01) Mazagon Dock Q1 PAT soars 121% YoY to Rs 225 cr  
  •  ( 09:34) Indices open on firm note; Nifty above 17,650  
  •  ( 09:25) Market breadth was strong  
  •  ( 09:19) HEG Q1 PAT spurts 180% YoY to Rs 159 cr  
  •  ( 08:36) Asian stocks trading higher  
  •  ( 08:25) Wall Street soars as inflation falls more than expected in July  
  •  ( 07:53) Wipro launches cybersecurity offering for Australian govt  
Show News
11 August 2022 00:00
3404.90
(-0.22 %)
759.20
(2.75 %)
7316.25
(2.36 %)
15729.30
(0.55 %)
709.55
(-0.76 %)
4257.15
(0.35 %)
2453.60
(2.32 %)
962.05
(1.00 %)
1486.75
(1.42 %)
2612.35
(-1.04 %)
859.30
(1.27 %)
1078.95
(1.60 %)
1619.70
(1.14 %)
306.30
(-1.56 %)
1854.15
(1.46 %)
1867.25
(0.68 %)
1265.55
(-0.15 %)
8818.00
(-0.69 %)
19688.45
(-0.39 %)
153.55
(-1.38 %)
222.80
(-0.25 %)
2590.20
(0.32 %)
524.55
(1.95 %)
920.00
(0.07 %)
109.10
(-0.14 %)
3422.45
(1.98 %)
1077.15
(2.12 %)
2471.60
(1.63 %)
6595.35
(0.06 %)
438.40
(1.93 %)
Sensex 5min and Nifty 15min delayed as on .
Show Ticker
Rotate your device

Rotate your device

For the best experience please go back to portrait mode.